Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)

NCT01437891 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2012-02-06

No results posted yet for this study

Summary

An open-label clinical outcomes study to determine the safety and efficacy of Sentra AM® and Sentra PM® for post-traumatic stress disorder (PTSD) and Gulf War fibromyalgia (GWF).

Conditions

  • Post-traumatic Stress Disorder
  • Persian Gulf Syndrome

Sponsors & Collaborators

  • Stephanie Pavlik

    lead INDUSTRY

Principal Investigators

  • William Shell, MD · Targeted Medical Pharma, Inc.

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437891 on ClinicalTrials.gov